Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233817 | 0.86 | GCGR (0.35) | NPC1GAAMAPK1RAB9AFBP1 | |
| SCHEMBL21211234 | 0.78 | NPC1 (0.38) | NPC1GAAMAPK1RAB9A | |
| SCHEMBL21316117 | 0.78 | NPC1 (0.38) | NPC1GAAMAPK1RAB9A | |
| SCHEMBL17480640 | 0.78 | — | — | |
| SCHEMBL17481211 | 0.78 | GRM5 (0.34) | — | |
| SCHEMBL7233939 | 0.72 | NPC1 (0.33) | NPC1GAAMAPK1RAB9A | |
| SCHEMBL9644316 | 0.71 | PKM (0.38) | NPC1GAAMAPK1RAB9A | |
| SCHEMBL6901677 | 0.70 | NPC1 (0.46) | NPC1GAAMAPK1RAB9A | |
| SCHEMBL15796727 | 0.70 | COMT (0.42) | NPC1GAAMAPK1RAB9AFBP1 | |
| SCHEMBL22774947 | 0.68 | NPC1 (0.40) | NPC1GAAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| US-20190112312-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112312-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | NPC1 4651/4885GAA 1472/4885MAPK1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.